|
Market Closed -
Nasdaq
01:30:00 29/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 1.190 USD | +5.31% |
|
-4.80% | -34.62% |
Company Valuation: Alzamend Neuro, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 5.453 | - |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 25.72% | - |
| Enterprise Value (EV) | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 5.453 | 5.453 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 25.72% | 0% |
| P/E | -7.29x | -3.65x | -0.48x | -0.52x | -0.43x | -1.08x | -1.3x |
| PBR | 7.3x | - | -1.85x | - | 6.62x | 28.3x | -1.79x |
| PEG | - | -0.51x | 0x | 0x | 0x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.67x | -0.67x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.5x | -0.5x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -189 | -202.5 | -132.3 | -11.32 | -2.63 | -1.05 | -0.87 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | -7.907 | -11.26 | -8.931 | -4.121 | -7.949 | -8.2 | -8.2 |
| EBIT 1 | -12.32 | -14.87 | -9.938 | -4.497 | -8.767 | -10.8 | -10.8 |
| Net income 1 | -12.36 | -14.88 | -9.948 | -5.105 | -8.772 | -10.8 | -10.8 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 1,377.000 | 738.855 | 63.990 | 5.940 | 1.140 | 1.130 | 1.130 |
| Nbr of stocks (in thousands) | 68.9 | 71.8 | 76.3 | 734 | 3,805 | 4,826 | - |
| Announcement Date | 19/07/22 | 27/07/23 | 30/07/24 | 22/07/25 | 22/07/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.08x | - | - | - | 54.53L | |
| 17.08x | 6.33x | 12.4x | 1.75% | 6.35TCr | |
| 30.03x | 7.96x | 26.08x | 0.05% | 5.45TCr | |
| 37.03x | 6.57x | 19.63x | 0.87% | 5.36TCr | |
| 35.05x | 3.37x | 14.55x | -.--% | 4.48TCr | |
| 48.28x | 5.55x | 30.42x | -.--% | 4.16TCr | |
| -19.33x | 186.93x | -20.57x | -.--% | 3.99TCr | |
| 30.28x | 7.94x | 20.6x | 0.4% | 3.25TCr | |
| 36.51x | 6.64x | 22.27x | -.--% | 2.67TCr | |
| 26.96x | 5.67x | 14.71x | -.--% | 2.34TCr | |
| Average | 24.08x | 26.33x | 15.57x | 0.34% | 3.8TCr | |
| Weighted average by Cap. | 26.55x | 25.23x | 15.68x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZN Stock
- Valuation Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
